Active Ingredient(s):Amifampridine FDA Approved: * November 28, 2018 Pharm Company: *CATALYST PHARMA INC Category:Immune System
Amifampridine is used as a drug, predominantly in the treatment of a number of rare muscle diseases. The free base form of the drug has been used to treat congenital myasthenic syndromes and Lambert–Eaton myasthenic syndrome (LEMS) through compassionate use programs since the 1990s and was recommended as a first line treatment for LEMS in 2006, using ad hoc forms of the drug, since there was no marketed form.
Around 2000 doctors at Assistance Publique – Hôpitaux de Paris crea...
* May have multiple approval dates, manufacturers, or labelers.